论文部分内容阅读
一个国际研究小组公布研究报告说,对一种针对艾滋病病毒Ⅰ型的新一代强效广谱中和抗体进行的首个临床试验,取得明显效果。研究人员认为,这种抗体有望在艾滋病预防和治疗中发挥重要作用。参与这项研究的科隆大学医院8日发表新闻公报说,这个研究小组在I期临床试验中给艾滋病病毒Ⅰ型感染者一次注射最高剂量(每千克体重30毫克)这种名为“3BNC117”的抗体后,病人体内艾滋病病毒量明显减少,病毒血症明显受抑制达28天。试验还表明,这种抗体具有良好
An international team released a research report saying that the first clinical trial of a new generation of potent broad-spectrum neutralizing antibodies against HIV type I achieved significant results. The researchers believe that this antibody is expected to play an important role in the prevention and treatment of AIDS. The Cologne University Hospital, which participated in the study, said in a press release on the 8th that the team injected the highest dose (30 mg / kg body weight) of HIV-1 infection in a phase I clinical trial called “3BNC117 ”After the antibody, the patient’s HIV amount was significantly reduced, viremia was significantly inhibited for 28 days. Experiments also show that this antibody is good